Skip to content
PeptideHormone

CJC-1295

A long-acting GHRH analog engineered to stretch GH pulses.

AnalogLimitedBased on Growth-hormone-releasing hormoneCompare with GHRH Compare lineage

Built to stretch a pulse — an interesting question about whether an axis tuned by its timing can be lengthened without being flattened.

Identity

Class
GHRH(1-29) analog (with or without a drug-affinity complex)
Source
Synthetic analog of GHRH
Receptor
GHRH receptor (GHRHR), a class B GPCR

Key properties

Evidence floorClinicalREF1CLIN1
Molecular weight
≈ 3,647 Da
REF
Half-life (native)
~6-8 days (DAC form); ~30 min without DAC
CLIN

Approximate values for the native hormone; engineered analogs are often deliberately larger and far longer-acting. Each figure carries its own provenance tier, and the floor is the weakest of them - the Standard.

Mechanism

CJC-1295 is a modified GHRH(1-29) that resists DPP-4 degradation and, in its drug-affinity-complex (DAC) form, binds circulating albumin to extend its half-life from minutes to days — sustaining GHRH-receptor stimulation and elevating GH and IGF-1 over a prolonged window. Because it drives the pituitary rather than replacing GH, secretion stays broadly pulsatile and feedback-regulated.

Reference notes

  • Two forms circulate under one name: the DAC version is long-acting (days), while the widely sold 'no-DAC' form (modified GRF 1-29) acts over roughly half an hour.
  • A 2006 human study showed the DAC form sustained GH and IGF-1 elevations for about a week per dose.
  • It is an unapproved research compound; controlled long-term human safety and efficacy data are sparse.

Common questions

What is CJC-1295?
A long-acting GHRH analog engineered to stretch GH pulses. Structurally it is GHRH(1-29) analog (with or without a drug-affinity complex).
How does CJC-1295 work?
CJC-1295 is a modified GHRH(1-29) that resists DPP-4 degradation and, in its drug-affinity-complex (DAC) form, binds circulating albumin to extend its half-life from minutes to days — sustaining GHRH-receptor stimulation and elevating GH and IGF-1 over a prolonged window. Because it drives the pituitary rather than replacing GH, secretion stays broadly pulsatile and feedback-regulated.
How strong is the evidence for CJC-1295?
PeptideHormone grades CJC-1295 at the "Limited" evidence tier — the evidence is sparse, older, or mostly community-reported. It is catalogued as an engineered analog built on an endogenous hormone, and the tier is an editorial judgment about the public literature that can change as the science does.
What is the half-life of CJC-1295?
The reported circulating half-life of CJC-1295 is ~6-8 days (DAC form); ~30 min without DAC.

Selected literature

Curated peer-reviewed reviews, sourced from PubMed. Selected for relevance, not exhaustive — open any entry on PubMed for the full record and its primary citations.

  1. 1.Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults · The Journal of clinical endocrinology and metabolism, 2006 · PMID 16352683
  2. 2.Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance · Sports medicine (Auckland, N.Z.), 2026 · PMID 41966639
  3. 3.Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions · Substance use & misuse, 2016 · PMID 26771670

External references

CJC-1295 in the public knowledge graph — the same entity resolved across the authoritative chemistry and protein databases.